Form 8-K Intra-Cellular Therapies For: Oct 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
October 30, 2024 4:38 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $79.00 (from $74.00) while maintaining a Neutral rating.
The analyst comments "Focus remains on commercial execution ahead of MDD launch. ITCI reported 3Q24 revenues of $175.4M, slightly higher than FactSet consensus ($172.3M, +2%) and in-line with GS estimate ($175.2M, 0%). The company also modestly raised and narrowed the range... More
